We have developed synthetic double-stranded oligodeoxynucleotides (ODN) as 'decoy' cis elements that block the binding of nuclear factors to promoter regions of targeted genes, resulting in the inhibition of gene transactivation in vivo. In the present study, we employed decoy ODN targeting the transcription factor nuclear factor-kappaB (NFkappaB) binding cis-elements to hepatic metastasis of murine reticulosarcoma M5076 in mice. Intravenous inoculation of M5076 into mice caused a marked increase in gene expression of interleukin-1␤, tumor necrosis factor-␣ and intercellular adhesion molecule-1 in the liver, whereas intravenous treatment with NF-kappaB decoy ODN reduced M5076-induced transactivation of these genes. Treatment
Introduction
Metastasis is the ability of tumor cells to disseminate and colonize at distant organs and is the most malignant characteristic of cancer. Despite improvements in surgical techniques and adjuvant therapies, metastasis is a major cause of death in cancer patients and therefore is a major obstacle to the successful treatment of cancer. 1 Clinical and experimental observations have revealed that cancer metastasis occurs via multiple and sequential cascades of events such as detachment from the primary tumor, transport in the circulation, adhesion to the microvascular endothelium of distant organs, extravasation and finally, proliferation as a metastatic tumor. [1] [2] [3] [4] Although a variety of mechanisms or factors have been postulated to be involved in the development of metastasis, it is proposed that adhesion of tumor cells to the microvascular endothelium is one of the crucial steps in the development of metastasis, 5, 6 and also that a variety of adhesion molecules including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 and E-selectin play a key role in the adhesion of tumor cells to with NF-kappaB decoy ODN, but not scrambled decoy ODN, significantly inhibited hepatic metastasis of M5076 in mice, and furthermore the combined treatment of NF-kappaB decoy ODN with an anti-cancer drug resulted in complete inhibition of hepatic metastasis in half of the mice, without affecting myelosuppression induced by the anti-cancer drug. Here, NF-kappaB decoy ODN inhibited hepatic metastasis of M5076 in mice possibly through a decrease in transactivation of important NF-kappaB-driven genes and also potentiated the anti-metastatic effect of an anti-cancer drug, demonstrating the first successful in vivo therapy for cancer metastasis using NF-kappaB decoy ODN as a novel molecular decoy approach. Gene Therapy (2001) 8, 905-912. microvascular endothelium. [7] [8] [9] [10] In addition, recent studies have shown that inflammatory immunomediators such as interleukin-1␤ (IL-1␤) and tumor necrosis factor-␣ (TNF-␣) can activate specific adhesive mechanisms on endothelial cells, mediating their interaction with circulating cells. [11] [12] [13] [14] The regulation of these cytokines and adhesion molecules including IL-1␤, TNF-␣ and ICAM-1 has been reported to be dependent on the transcription factor nuclear factor-kappaB (NF-kappaB). [15] [16] [17] In this study, we focused on the role of NF-kappaB in the pathogenesis of cancer metastasis. Recently, the decoy strategy has been developed and considered a useful tool as a new class of anti-gene strategy. 18, 19 Transfection of double-stranded oligodeoxynucleotides (ODN) as decoy corresponding to the cis sequence results in attenuation of the authentic cistrans interaction, leading to the removal of the trans-factors from the endogenous cis-element, with subsequent modulation of gene expression. 18, 19 Therefore, the decoy approach enables us to treat diseases by modulating endogenous transcriptional regulation. [20] [21] [22] [23] We hypothesized that tumor metastasis may be inhibited by the transfection of NF-kappaB decoy ODN if the expression of cytokines and adhesion molecules involved in the tumor cell-vasculature interactions, the most important step in the metastatic process, is suppressed by NF-kappaB decoy ODN in vivo.
Murine reticulosarcoma M5076, which arose spon-Gene Therapy taneously in the ovary of C57BL/6 mouse, 24 has been reported to have the ability to form preferentially metastatic colonies in the peritoneal viscera such as liver, spleen and ovary regardless of the site or route of tumor cell injection. 25 This tumor is often used for evaluation of the anti-metastatic activity of a drug. 26, 27 In this study we employed NF-kappaB decoy ODN to hepatic metastasis of M5076 reticulosarcoma in mice, in order to evaluate the role of transcription factor NF-kappaB in the pathogenesis of cancer metastasis.
Results
Detection of FITC-labeled ODN after systemic transfection Initially, we studied the localization of FITC-labeled decoy ODN to evaluate the transfection efficiency of ODN delivery by the Sendai-virus (HVJ)-liposome method, which is reported to bypass endocytosis, thereby avoiding degradation in lysosomes. [20] [21] [22] At 30 min after transfection, fluorescence was readily detected in the liver, spleen and kidney (tubular cells, but not in mesangial cells) with the HVJ-liposome method, whereas no fluorescence was observed in brain, lung (Figure 1a) , heart, muscle, or intestine (data not shown). In contrast, passive uptake of FITC-labeled ODN without vector resulted in the detection of fluorescence mainly in kidney, but with some detected in liver and spleen ( Figures  1b-d) . In other tissues, no fluorescence was observed with passive uptake. Interestingly, a striking difference in time course for detection of fluorescence was observed between the HVJ-liposome method and passive uptake (Figures 1b-d) . Rapid disappearance of fluorescence (within 1 day) was found with passive uptake, whereas all eight mice (100%) transfected with FITC-labeled ODN using the HVJ-liposome method exhibited apparent evidence of fluorescence for at least 2 weeks (data not shown). Fluorescence resulting from FITC-labeled ODN was easily distinguished from background auto-fluorescence. Systemic administration of free FITC did not result in specific fluorescence in the tissues (data not shown), demonstrating that this fluorescence was specific for FITC-labeled decoy ODN. Untreated or HVJ complex without FITC-ODN resulted in no specific fluorescence (data not shown). We also performed transfection of FITC-labeled ODN of two other different sequences. There were no significant differences in localization or duration of fluorescence (data not shown). In the present study we confirmed the prolongation of ODN half-life with the HVJ-liposome method, which is consistent with previous reports. [18] [19] [20] Marked transfection efficiency of ODN was also confirmed by the measurement of fluorescence. As shown in Figure 1e , transfection of FITClabeled ODN by HVJ-liposome method (1 m) resulted in a significant increase in fluorescence of the tissues as compared with direct transfer (10 m, 'naked') (P Ͻ 0.01) at 1 day after transfection. No apparent damage in the tissues transfected with decoy ODN was observed on hematoxylin-eosin staining (data not shown).
Transfection of NF-kappaB decoy ODN into mice inoculated with M5076 cells Of importance, the binding affinity of NF-kappaB as assessed by gel mobility shift assay was markedly increased in the liver of mice inoculated with M5076 as compared with that of untreated mice (Figure 2a) . Moreover, complete competition for the increased binding of NF-kappaB by an excess amount of NF-kappaB decoy ODN, but not scrambled decoy ODN, was observed (Figure 2b ), consistent with previous reports. 21, 22 We therefore examined the inhibitory effects of transfection of NF-kappaB decoy ODN on the hepatic metastasis, given the accumulation of transfected decoy ODN in the liver.
Effect of NF-kappaB decoy ODN on hepatic metastasis of M5076 cells Anti-metastatic effect of NF-kappaB decoy ODN was next investigated in the M5076 tumor system in mice. Interestingly, treatment with NF-kappaB decoy ODN (30 m) resulted in a significant decrease in the number of hepatic colonies of M5076, by 80%, as compared with the vehicle-treated mice. Scrambled decoy ODN also decreased hepatic colonies by 28%, but it was not statistically significant ( Figure 3 ). As shown in Figure 4 , the size of metastatic colonies of M5076 tumor was also decreased by NF-kappaB decoy ODN treatment, but not by scrambled decoy ODN. Neither NF-kappaB nor scrambled decoy ODN had an effect on the body weight of mice (data not shown). In addition, we examined the direct effect of NF-kappaB decoy ODN on the growth of M5076 reticulosarcoma cells in vitro. Unexpectedly, the growth of M5076 cells was not affected by 2 or 3 days incubation with NF-kappaB decoy ODN and scrambled decoy ODN (date not shown). These results suggest that the inhibitory effect of NF-kappaB decoy ODN on metastasis is probably not due to the direct inhibition of M5076 reticulosarcoma cell growth.
To understand further the molecular mechanisms underlying the inhibitory action of NF-kappaB decoy ODN on metastasis induced by M5076 reticulosarcoma cells, we measured IL-1␤, TNF-␣ and ICAM-1 mRNA in the liver. At 24 h after inoculation of M5076 cells, expression of genes of IL-1␤, TNF-␣ and ICAM-1 was markedly increased in the liver as compared with that in untreated mice ( Figure 5 ). In contrast, expression of genes of IL-1␤, TNF-␣ and ICAM-1 was markedly decreased in the liver of mice transfected with NF-kappaB decoy ODN.
Combined effect of NF-kappaB decoy ODN and an anticancer drug on metastasis of M5076 reticulosarcoma cells In the completion of our study, anti-metastatic effect of NF-kappaB decoy ODN on M5076 metastasis was investigated in mice in combination with an anti-cancer drug, Table 1 , the number of M5076 metastatic colonies on the surface of the liver was significantly decreased by treatment with NF-kappaB decoy or MMC (3.2 mg/kg), by 77% or 92%, respectively, and the combined treatment of NF-kappaB decoy ODN with MMC resulted in a marked inhibition of metastasis. Of particular interest, five mice among 10 were free of hepatic metastasis by combined treatment of NF-kappaB decoy ODN with MMC (3.2 mg/kg). Scrambled decoy ODN slightly inhibited the hepatic metastasis of M5076, but did not show a significant potentiation on the anti-metastatic effect of MMC in mice.
Figure 1 In vivo transfer of FITC-labeled ODN. (a) Representative fluorescence microscopy of various organs of mice transfected with FITC-labeled ODN by HVJ-liposome method at 1 day after transfection. (b-d) Comparison of HVJ-liposome method and passive uptake in liver (b), spleen (c) and kidney (d). HVJ, mice transfected with FITC-labeled

mitomycin C (MMC). As shown in
In order to investigate the combined effect of NF-kappaB decoy ODN and MMC on myelosuppression in mice, blood parameters were examined on day 11. As shown in Table 2 , MMC treatment caused a significant decrease in the number of WBC, RBC and platelets, whereas NFkappaB decoy or scrambled decoy ODN had no effect on these numbers regardless of single use or combination with MMC, demonstrating that NF-kappaB decoy ODN potentiates the anti-metastatic effect of MMC, but not MMC-induced myelosuppression in mice.
Discussion
The decoy strategy using a double-stranded ODN corresponding to the cis sequence has been recently developed as a new class of anti-gene strategy, 18, 19 and the decoy approach enables us to treat diseases by modulating endogenous transcriptional regulation. We have recently revealed that the strategy using transcription factor-targeting decoy ODN is able to regulate the expression of targeted genes and produce a therapeutic effect in vivo. [20] [21] [22] [23] In the present study, we investigated the anti-metastatic effect of NF-kappaB decoy ODN on M5076 hepatic metastasis in mice, to understand the role of the transcription factor NF-kappaB in the pathogenesis of cancer metastasis. At first, we investigated the localization and duration of decoy ODN after intravenous transfection of ODN delivery by HVJ-liposome method using FITClabeled decoy ODN. Fluorescence was readily detected in the liver, spleen and kidney (Figures 1a-e) , and the fluorescence in the liver was detected for up to at least 2 weeks after intravenous transfection. These results suggest that expression of targeted genes in the targeted organs such as liver, spleen and kidney can be regulated by intravenous transfection of decoy ODN by the HVJliposome method in mice. Furthermore, our subsequent gel mobility shift assay, of particular interest, shows that the binding affinity of NF-kappaB was markedly increased in the liver 24 h after injection of M5076 cells (Figures 2a and b) , suggesting the involvement of NFkappaB in the early process of hepatic metastasis of M5076 reticulosarcoma cells.
These findings encouraged us to investigate the potential utility of NF-kappaB decoy ODN for the treatment of hepatic metastasis of M5076 in mice. As a result, the present study, of importance, has shown that intravenous transfection of NF-kappaB decoy ODN reduces the transactivation of genes of important factors IL-1␤, TNF-␣ and Gene Therapy The method is shown in the legend of Table 1 . Hematological parameters were examined in mice 11 days after tumor inoculation. Mice were used in groups of 10. SD, scrambled decoy ODN; NF, NF-kappaB decoy ODN. a P Ͻ 0.01, compared with control mice (Dunnett test).
ICAM-1 in the liver, and thereby inhibits hepatic metastasis of M5076 in mice (Figures 3 and 5) . Recently several lines of evidence have demonstrated the involvement of the transcription factor NF-kappaB in the development of cancer metastasis. [28] [29] [30] [31] However, most of this evidence has come from in vitro experimental systems such as cell adhesion assays via attachment molecules, and there are few published in vivo studies. This study is thus believed to be the first successful in vivo application of decoy as a novel molecular therapy for cancer metastasis. It should be noted though that in this study we performed the in vivo distribution of FITC-labeled decoy ODN at only 1 m, whereas the therapeutic dose employed was 30 m. Higher doses of NF-kappaB decoy ODN might demonstrate slightly different distribution patterns and raise other possible mechanisms for the inhibitory effects of NF-kappaB decoy ODN on M5076 metastasis.
Additionally, the decrease in colony size of hepatic metastasis was also observed in mice transfected with NF-kappaB decoy ODN (Figure 4 ). Since NF-kappaB has been implicated in the regulation of cell proliferation, transformation and tumor development, [32] [33] [34] it is possible that the direct growth inhibition of metastasized M5076 cells in the liver by NF-kappaB decoy ODN transfection might be at least partly attributable to its decrease in the number and size of M5076 hepatic metastases. However, when the direct effect of NF-kappaB decoy ODN on the growth of M5076 reticulosarcoma cells was examined in vitro, cell growth of M5076 was not affected by 2 or 3 day incubation with NF-kappaB decoy ODN (data not shown), indicating that the inhibitory effect of NF-kappaB decoy ODN on metastasis is not due to the direct inhibition of growth of M5076 reticulosarcoma cells. NFkappaB decoy ODN may interfere with the homing of M5076 cells in the liver, their growth factor response, cell adhesion, or many other putative biological functions. These results suggest that NF-kappaB decoy strategy shows promise as an anti-metastatic therapeutic regimen.
As mentioned above, activation of the transcription factor NF-kappaB and transactivation of targeted genes such as IL-1␤, TNF-␣ and ICAM-1 were both observed in the liver of mice at 24 h after M5076 inoculation ( Figure 5 ). M5076 murine reticulosarcoma has the ability to form preferentially metastatic colonies in the liver and spleen, 25, 26 and is an appropriate experimental tumor system for evaluating the anti-metastatic activity of a drug. 27 However, little is known in the literature about the mechanism or the factors underlying the development of M5076 metastasis. From the results of this study, it is suggested that M5076 activates NF-kappaB in the liver, which in turn induces activation of IL-1␤, TNF-␣ and ICAM-1 and thereby facilitates attachment of M5076 to endothelial cells. The finding of the present study, to the best of our knowledge, is the first to show an important role of the transcription factor NF-kappaB in the development of hepatic metastasis of M5076 reticulosarcoma.
The goal of anti-metastatic therapy is the complete inhibition of metastasis, because if only one metastatic colony is formed in an organ, it may result in the death of the host after some time. In this sense, the anti-metastatic activity of NF-kappaB decoy ODN against M5076 reticulosarcoma is considered to be far from satisfactory, although it is interesting to note that the hepatic metastasis was inhibited by treatment with NF-kappaB decoy ODN by as much as 80% in our present study. Therefore, in the completion of our study, we examined the combined treatment of NF-kappaB decoy ODN with an anticancer drug MMC on metastasis of M5076 in mice. Interestingly, our present study revealed that the combined treatment of NF-kappaB decoy ODN with MMC resulted in complete inhibition of metastasis in the livers of five mice among 10, without affecting the hematological toxicity of MMC (Tables 1 and 2 ). Thus, NF-kappaB decoy showed potentiation on the anti-metastatic activity, but not on the myelosuppression, of MMC in M5076-bearing mice. Since the liver is one of the most common metastatic organs for a variety of human malignant tumors, inhibition of hepatic metastasis is expected to be important in the successful treatment of cancer. 5, 6 It is therefore of particular importance to note that NF-kappaB decoy ODN is able to produce complete inhibition of hepatic metastasis induced by M5076 in combination with the anti-cancer drug MMC, providing a potential clinical utility of NF-kappaB decoy ODN for the treatment of cancer metastasis.
Overall, the present study demonstrates that intravenous transfection of NF-kappaB decoy ODN, but not scrambled decoy ODN, inhibits hepatic metastasis of M5076 in mice possibly through a decrease in the transactivation of important NF-kappaB-driven genes IL-1␤, TNF-␣ and ICAM-1 in the liver. NF-kappaB decoy ODN potentiated the anti-metastatic effect, but not the myelosuppression, of the anti-cancer drug MMC in M5076-bearing mice. These data demonstrate the first successful in vivo therapeutic application of NF-kappaB decoy ODN as a novel molecular approach for cancer metastasis.
Materials and methods
Animals and tumor cells Specific pathogen-free female C57BL/6 mice were purchased from Charles River Japan Inc. (Kanagawa, Japan). Mice were kept in conditions of constant temperature and humidity and fed a standard diet and water ad libitum. Murine M5076 reticulosarcoma cells were maintained by 10-day serial passage in ascites fluid in C57BL/6 mice.
Experimental hepatic metastasis
Single cell suspension of M5076 (1 × 10 4 cells in 200 l of buffered saline) was inoculated into the lateral tail vein of mice. In the experiment to investigate the anti-metastatic effect of NF-kappaB decoy ODN, 200 l of NF-kappaB decoy or scrambled decoy ODN was administered in the lateral tail vein of mice at 24 and 2 h before, and 24 h after M5076 cell inoculation. In the other experiment to examine the anti-metastatic effect by combination of NF-kappaB decoy ODN and an anti-cancer drug MMC (Kyowa Hakko Kogyo Co., Tokyo, Japan), 200 l of NFkappaB decoy or scrambled decoy ODN was administered in the lateral tail vein of mice at 24 and 2 h before, and 24 h after M5076 cell inoculation and MMC, which was dissolved in and diluted with saline, was administered in the lateral tail vein of mice three times every 3 days, starting 1 day after the tumor inoculation. To examine the blood parameters of mice, blood was obtained from the retro-orbital sinus by capillary under light ether anesthesia on day 11. Mice were killed on day 14 and the livers were harvested and fixed in Bouin's solution. The resulting visible metastatic colonies on the surface of the livers were counted under a dissecting microscope.
In vitro cell growth test against M5076 reticulosarcoma cells The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma Chemical, St Louis, MO, USA) assay was used to evaluate the effect of NF-kappaB decoy ODN on M5076 reticulosarcoma cells in vitro. Cells were incubated in 96-well microtiter plates (5 × 10 3 cells/well) in 100 l of RPMI medium (Sigma Chemical) supplemented with 10% fetal bovine serum, 50 units/ml penicillin, 50 g/ml streptomycin (Flow Laboratories, North Ryde, Australia) plus 25 l of NF-kappaB decoy ODN (30 m) or scrambled decoy ODN for 48 or 72 h at 37°C in a humid atmosphere in the presence of 5% CO 2 . After the addition of MTT (10 l/well, 5 mg/ml in phosphate-buffered saline), the plates were incubated for 4 h. . The complex was injected intravenously into the lateral tail vein of mice. Thirty min, 12 and 24 h, and 3, 7 and 14 days after transfection, mice were killed, and tissues were removed after perfusion-fixation with 4% paraformaldehyde under physiological pressure. Sections were examined by fluorescent microscopy, after staining in erichrome black T solution. Elastic fibers stained dark red were readily distinguishable from the specific FITC ODN after treatment with erichrome black T solution (data not shown), as previously described. 35, 36 We also performed quantitative measurement of fluorescence to confirm the efficiency of FITC-labeled ODN transfection with the HVJ-liposome method (1 m).
37
FITC-labeled ODN with HVJ-liposome complex was intravenously injected into the tail vein. For measurement of fluorescence, tissues were then extracted at 1 day after transfection. They were homogenized in 1 ml of PBS, centrifuged and 400 l of the supernatant was used for measurement with a fluorescence meter (RF1500 spectrofluorophotometer, Shimazu) (excitation, 493 nm; emission, 520 nm).
Preparation of HVJ-liposomes
Phosphatidylserine, phosphatidylcholine, and cholesterol were mixed in a weight ratio of 1:4.8:2, respectively. [36] [37] [38] [39] The lipid mixture (10 mg) was deposited on the sides of a flask by removal of tetrahydrofuran in a rotary evaporator. Dried lipid was hydrated in 200 l balanced salt solution (BSS; 137 nm NaCl, 5.4 mm KCl, 10 mm TrisHCl; pH 7.6). The control group liposomes did not contain ODN (BSS 200 l). Liposomes were prepared by shaking and sonication. Purified HVJ (Z strain) was inactivated by UV irradiation (110 erg/mm 2 /s) for 3 min just Gene Therapy before use. The liposome suspension (0.5 ml, containing 10 mg lipid) was mixed with HVJ (10 000 hemagglutinating units) in a total volume of 4 ml BSS. The mixture was incubated at 4°C for 5 min and then for 30 min with gentle shaking at 37°C. Free HVJ was removed from the HVJ-liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use. The final concentration of decoy ODN was equivalent to 30 m, as calculated according to previous reports. 22 This preparation method has been optimized to achieve maximal transfection efficiency, as reported previously. [36] [37] [38] [39] Gel mobility shift assay Nuclear extracts were prepared from the liver of mice inoculated with or without cancer cells, as described previously. 20, 22 In brief, livers were homogenized with a Potte-Elvehjem homogenizer in four volumes of ice-cold homogenization buffer (10 mm Hepes, 0.5 m sucrose, 0.5 mm spermidine, 0.15 mm spermin, 5 mm EDTA, 0.25 m EGTA, 7 mm ␤-mercaptoethanol, 1 mm phenylmethylsulfonyl fluoride; pH 7.5). After centrifugation at 12 000 g for 30 min at 4°C, each pellet was lysed in one volume of ice-cold homogenization buffer containing 0.1% NP-40 by homogenizing in a Dounce homogenizer. It was then centrifuged at 12 000 g for 30 min at 4°C and the pellet nucleus was washed twice with ice-cold buffer containing 0.35 m sucrose. After washing, the nucleus was preextracted with 1 volume of ice-cold homogenization buffer containing 0.05 m NaCl and 10% glycerol for 15 min at 4°C. Nucleus was then extracted with homogenization buffer containing 0.3 m NaCl and 10% glycerol for 1 h at 4°C, and the concentration of DNA was adjusted to 1 mg/ml. After pelleting the extracted nucleus at 12 000 g for 30 min at 4°C, the supernatant was added to 45% (NH 4 ) 2 SO 4 and stirred for 30 min at 4°C. The precipitated protein was collected at 17 000 g for 30 min, resuspended in homogenization buffer containing 0.35 m sucrose, and stored in aliquots at −70°C.
NF-kappaB and scrambled decoy ODN were labeled as a primer at the 3Ј end by 3Ј endo-labeling kit (Clontech, Palo Alto, CA, USA). After endo-labeling, 32 Plabeled ODN were purified by application to Nick column (Pharmacia). Binding mixtures (10 l) including 32 Plabeled primer (0.5-1 ng, 10 000-15 000 c.p.m.), and 1 g polydeoxyinosinic-deoxycytidic acid (Sigma Chemical) were incubated with 10 g nuclear extract for 30 min at room temperature and then loaded on to a 5% polyacrylamide gel. The gels were subjected to electrophoresis, dried, and pre-incubated with parallel samples 10 min before the addition of the labeled probe. As a control, samples were incubated with an excess (50 ×, 100 ×) of nonlabeled NF-kappaB ODN which completely abolished binding. Gels were analyzed by autoradiography.
Northern blot analysis
Transfection of NF-kappaB or scrambled decoy ODN was performed, as described above. RNA was extracted by RNAzol (Tel-Test, TX, USA), from the liver of mice inoculated with M5076 cells, and scrambled or NF-kappaB decoy ODN (30 m) at 24 h after transfection by the HVJliposome method (30 m within HVJ-liposome complex), for Northern blot analysis. 22 For Northern blot analysis, 20 g of total RNA was subjected to electrophoresis on 1.5% agarose-formaldehyde denaturing gel and trans-ferred to a nitrocellulose membrane (Amersham International, Amersham, UK). The filter was baked, prehybridized, and hybridized to GAPDH oligonucleotides (Clontech) or full length complementary DNA (cDNA) for IL-1␤, TNF-␣ and ICAM-1 were used as probes and labeled by 3Ј end-labeling for Northern blotting. The filter was then washed and exposed to X-ray film.
Statistical analysis
All values are expressed as mean ± s.e. All experiments were performed at least three times. Analysis of variance was performed and Dunnett test or Student's t-test was used to determine the significance of differences. Differences with values of P Ͻ 0.05 were considered significant.
